3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Completed
56
Unknown
53
Recruiting
39
Not yet recruiting
14
Active not recruiting
9
Enrolling by invitation
5
Terminated
4
Withdrawn
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Conditions
Breast Neoplasms
333
Neoplasms
221
Prostatic Neoplasms
197
Carcinoma, Non-Small-Cell Lung
156
Lung Neoplasms
135
Pancreatic Neoplasms
118
Colorectal Neoplasms
103
Neoplasm Metastasis
100
Carcinoma, Hepatocellular
96
Leukemia, Myeloid, Acute
94
Multiple Myeloma
91
Brain Neoplasms
89
Lymphoma
86
Head and Neck Neoplasms
76
Melanoma
73
Ovarian Neoplasms
72
Leukemia
71
Leukemia, Lymphocytic, Chronic, B-Cell
69
Glioblastoma
69
Precursor Cell Lymphoblastic Leukemia-Lymphoma
66
Colonic Neoplasms
61
Recurrence
59
Lymphoma, Non-Hodgkin
54
Rectal Neoplasms
50
Hematologic Neoplasms
50
Lymphoma, Follicular
49
Glioma
49
Squamous Cell Carcinoma of Head and Neck
47
Lymphoma, Large B-Cell, Diffuse
47
Carcinoma, Renal Cell
47
Interventions
Nivolumab
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Withdrawn
×
OTHER
×
Lymphatic Metastasis
×
Clear all
NCT05504642
2023-04-18
CERAD-IMMUNE
Universitätsklinikum Köln
Phase 2
Withdrawn
NCT02341170
2019-04-17
HIPPO-S
Universitätsmedizin Mannheim
Phase NA
Withdrawn